Jei-keon Chae

Jeonju, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Jeonju, KR 

Overview

Jei-keon Chae practices practicing medicine in Jeonju, Republic of Korea.

Their clinical expertise encompasses Heart Attack, Breast Cancer, Coronary Heart Disease, Mastectomy, and Percutaneous Coronary Intervention (PCI).

They are actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 7 clinical trials.

Locations

Jeonju, Republic of Korea
Other Locations
Jeollabuk Do, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial: Ischemia-guided Revascularization Using Perfusion Coronary CT vs. Fractional Flow Reserve
Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial: Ischemia-guided Revascularization Using Perfusion Coronary CT vs. Fractional Flow Reserve
Enrollment Status: Recruiting
Publish Date: April 05, 2023
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Enrollment Status: Completed
Publish Date: December 29, 2025
Intervention Type: Device
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Tailored antithrombotic strategy, Conventional antithrombotic strategy
Study Phase: Phase 4
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Device, Drug
Study Drug: Optimal Medical treatment
Study Phase: Phase 4
Perfusion CT Registry
Perfusion CT Registry
Enrollment Status: Completed
Publish Date: March 22, 2023
a Multi-center, Open-label, Nationwide Registry-based, Randomized, Pragmatic Trial Comparing 2 Post-PCI Management Strategies in High-risk PCI Patients With Complex Clinical and Lesion Characteristics
a Multi-center, Open-label, Nationwide Registry-based, Randomized, Pragmatic Trial Comparing 2 Post-PCI Management Strategies in High-risk PCI Patients With Complex Clinical and Lesion Characteristics
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
Enrollment Status: Completed
Publish Date: November 30, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

11 Total Publications

Complete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study.
Complete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study.
Journal: Journal of Yeungnam medical science
Published: November 05, 2024

Frequently Asked Questions about Jei-keon Chae

Is Jei-keon Chae a top-rated expert for Heart Attack?

MediFind is an objective health platform that identifies experts based on real-world data. Jei-keon Chae is classified as an Experienced expert for Heart Attack, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jei-keon Chae participate in research or clinical trials?

Yes. Jei-keon Chae has published 11 articles and abstracts on conditions like Heart Attack. You can view a list of Jei-keon Chae's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chae's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile